Dr. Paul Ladenson, senior endocrinological consultant for the study, stated, "Data from this rigorously conducted, placebo-controlled, double blind trial show that anatabine-treated subjects had progressive decreases in circulating thyroglobulin antibody levels, which became significant by the end of the trial. Current treatment for autoimmune thyroiditis is limited to end-stage disease when irreversible gland damage necessitates lifelong thyroid hormone replacement. The prospect of a novel nutritional or pharmaceutical intervention that could preserve thyroid health represents an encouraging advance. Further clinical studies are now warranted."
Thanks, Rick, for the heads up about this news release. Considering the preliminary information being released, when the final report is released it could create a lot of excitement. Wow, I'll bet that this notation by Dr. Curtis Wright "...The thyroglobulin levels in some patients returned entirely to normal in this three month study." could be significant by those who understand what this may mean.